Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.